122 ERCC1-negative tumors benefit from neoadjuvant cisplatin-based chemotherapy whereas patients with ERCC1-positive tumors do not – results from a cystectomy trial database
Authors:
- T. HemdanTHT. Hemdan
- U. SegerstenUSU. Segersten
- P-U. MalmströmPMP-U. Malmström
- 1 April 2014
- journal article
- Published by Elsevier in European Urology Supplements
- Vol. 13 (1) , e122